Trial Profile
A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary) ; Plerixafor
- Indications Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Pharmacodynamics
- 21 Dec 2016 Status changed from active, no longer recruiting to completed.
- 14 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.